Limaprost
CAS No. 74397-12-9
Limaprost ( 17α,20-dimethyl-δ2-PGE1,ONO1206,OP1206 )
Catalog No. M22940 CAS No. 74397-12-9
Limaprost is an analog of PGE1 with structural modifications intended to give it a prolonged half-life and greater potency.It is a potent and orally active vasodilator.?Limaprost increases blood flow and inhibits platelet aggregation.?Limaprost can be used for pain relief, has antianginal effects, and has potential for ?ischaemic symptoms treatment.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 185 | In Stock |
|
10MG | 338 | In Stock |
|
25MG | 806 | In Stock |
|
50MG | 1471 | In Stock |
|
100MG | Get Quote | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLimaprost
-
NoteResearch use only, not for human use.
-
Brief DescriptionLimaprost is an analog of PGE1 with structural modifications intended to give it a prolonged half-life and greater potency.It is a potent and orally active vasodilator.?Limaprost increases blood flow and inhibits platelet aggregation.?Limaprost can be used for pain relief, has antianginal effects, and has potential for ?ischaemic symptoms treatment.
-
DescriptionLimaprost is an analog of PGE1 with structural modifications intended to give it a prolonged half-life and greater potency.It is a potent and orally active vasodilator.?Limaprost increases blood flow and inhibits platelet aggregation.?Limaprost can be used for pain relief, has antianginal effects, and has potential for ?ischaemic symptoms treatment.By a concentration-dependent manner, Limaprost inhibits the IL-1-mediated induction of nerve growth factor (IC50: 70.9 ?nM human IVD cells) .PGE1 and limaprost exhibited a novel pharmacological action that suppresses NGF expression in human IVD cells, and other prostanoids differentially regulated NGF expression.?Limaprost has been used to treat patients with lumbar spinal stenosis in Japan and was proved to be effective in relieving symptoms.Platelet aggregation, adhesiveness, bleeding time, and thrombocytopenia induced by ADP and collagen infusion in guinea-pigs are inhibited by oral administration of Limaprost at the same doses or doses less than those relieving vasopressin-induced ST depression of ECG.?Intra-coronary injection of Limaprost (1-100 ng/kg) in dogs causes a remarkable increase in coronary blood flow without any influence on heart rate, blood pressure, myocardial oxygen consumption, and redox potential.?Limaprost given orally at more than 100 mg/kg relieves vasopressin-induced ST depression of rat electrocardiogram.?Resistance in both large and small vessels of the dog coronary artery is decreased by intravenous injection of Limaprost (1-3 mg/kg).
-
Synonyms17α,20-dimethyl-δ2-PGE1,ONO1206,OP1206
-
PathwayImmunology/Inflammation
-
TargetPGE synthase
-
RecptorPGE Synthase
-
Research Areanervous system
-
IndicationNeurologic Claudication in Patients With Lumbar Spinal Stenosis
Chemical Information
-
CAS Number74397-12-9
-
Formula Weight380.52
-
Molecular FormulaC22H36O5
-
Purity>98% (HPLC)
-
SolubilityDMSO:40 mg/mL (105.12 mM)
-
SMILESO=C(O)/C=C/CCCC[C@@H]1[C@@H](/C=C/[C@@H](O)C[C@@H](C)CCCC)[C@H](O)CC1=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Tsuboi T, et al. Pharmacological evaluation of OP 1206, a prostaglandin E1 derivative, as an antianginal agent. Arch Int Pharmacodyn Ther. 1980 Sep;247(1):89-102.
molnova catalog
related products
-
Benzydamine hydrochl...
A locally-acting nonsteroidal anti-inflammatory drug (NSAID) with local anaesthetic and analgesic properties for pain relief and anti-inflammatory treatment of inflammatory conditions.
-
mPGES1-IN-17d
mPGES1-IN-17d is a potent, selective mPGES-1 inhibitor with enzyme IC50 of 8 nM, A549 cell IC50 of 16.24 nM.
-
Crisdesalazine
Crisdesalazine (AAD-2004, AAD2004) is a derivative of aspirin that inhibits microsomal PGE(2) synthase-1 (mPGES-1) activity in response to both LPS-treated BV2 cell with IC50 of 230 nM and recombinant human mPGES-1 protein with IC50 of 249 nM in vitro.